Patents by Inventor David Duhl

David Duhl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8735599
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 27, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Xia Yia, Rustum S. Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan N. Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Patent number: 8664256
    Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: March 4, 2014
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Paul A. Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter
  • Publication number: 20140056880
    Abstract: The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.
    Type: Application
    Filed: August 28, 2013
    Publication date: February 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Tinya Abrams, Paul Barsanti, Yu Ding, David Duhl, Wooseok Han, Cheng Hu, Yue Pan
  • Patent number: 8546434
    Abstract: The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: October 1, 2013
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Paul Barsanti, Yu Ding, David Duhl, Wooseok Han, Cheng Hu, Yue Pan
  • Publication number: 20130017196
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 17, 2013
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Publication number: 20130012560
    Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.
    Type: Application
    Filed: July 11, 2012
    Publication date: January 10, 2013
    Inventors: Tinya Abrams, Paul Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter
  • Patent number: 8318791
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 27, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Patent number: 8252832
    Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: August 28, 2012
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Paul Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter
  • Patent number: 8129358
    Abstract: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: March 6, 2012
    Assignee: Novartis AG
    Inventors: Yi Xia, Kris G. Mendenhall, Paul A. Barsanti, Annette O. Walter, David Duhl, Paul A. Renhowe
  • Publication number: 20110256128
    Abstract: The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.
    Type: Application
    Filed: April 13, 2011
    Publication date: October 20, 2011
    Inventors: Tinya ABRAMS, Paul A. BARSANTI, Yu DING, David DUHL, Wooseok HAN, Cheng HU, Yue PAN
  • Patent number: 7902240
    Abstract: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: March 8, 2011
    Assignee: Novartis AG
    Inventors: Yi Xia, Kris Mendenhall, Paul A. Barsanti, Annette O. Walter, David Duhl, Paul A. Renhowe
  • Publication number: 20100034813
    Abstract: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:
    Type: Application
    Filed: November 8, 2007
    Publication date: February 11, 2010
    Inventors: Yi Xia, Kris G. Mendenhall, Paul A. Barsanti, Annette O. Walter, David Duhl, Paul A. Renhowe
  • Patent number: 7626040
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: December 1, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Barsanti, Yi Xia, Weibo Wang, Kris G. Mendenhall, Liana M. Lagniton, Savithri Ramurthy, Megan C. Phillips, Sharadha Subramanian, Rustum Boyce, Nathan M. Brammeier, Ryan Constantine, David Duhl, Annette O. Walter, Tinya J. Abrams, Paul A. Renhowe
  • Publication number: 20090258016
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: June 5, 2009
    Publication date: October 15, 2009
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Publication number: 20090239922
    Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.
    Type: Application
    Filed: November 25, 2008
    Publication date: September 24, 2009
    Inventors: Tinya Abrams, Paul Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter
  • Patent number: 7576221
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: August 18, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Patent number: 7456183
    Abstract: Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH2, N, NR9, C?O, C?S, S?O, SO2, S, O, (CR6R7)n, C(?O)—(CR6R7)n, and C(?S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of (formula I) and L is selected from the group consisting of N, O, S?O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r2) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: November 25, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Daniel Chu, Rustum Boyce, David Duhl, Bryan Chang
  • Publication number: 20080200462
    Abstract: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:
    Type: Application
    Filed: November 8, 2007
    Publication date: August 21, 2008
    Inventors: Yi Xia, Kris Mendenhall, Paul A. Barsanti, Annette O. Walter, David Duhl, Paul A. Renhowe
  • Patent number: 7329741
    Abstract: The present invention is a novel nucleic acid sequence which hybridizes to SEQ ID NO:6 or fragments thereof under stringent conditions, or fragments thereof. The invention also includes diagnostic assays, expression vectors, control sequences, antisense molecules, ribozymes, and host cells to express the polypeptide encoded by the nucleic acid sequence. The present invention also includes claims to the polypeptide sequence coded by the nucleic acid sequences.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: February 12, 2008
    Assignee: Chiron Corporation
    Inventor: David Duhl
  • Patent number: 7189727
    Abstract: Compounds having the general structure III are provided: where D is N or C; W is selected from Z1, Z2, and Z3 are independently selected from CR8 and N; and the other variables have the values described herein. Compounds of formula III have useful properties for controlling diseases related to MC4-R action in humans including obesity and type II diabetes.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: March 13, 2007
    Assignee: Chiron Corporation
    Inventors: Rustum Boyce, David Duhl